English 
Spanish 
Throughout May, June, and July, donations made to Parasites Without Borders (PWB) will be matched by the organization and donated to Foundation for International Medical Relief of Children (FIMRC), for a total gift of up to $10,000. Founded in 2002 by Dr. Vikram D. Bakhru, FIMRC is a U.S.-based nonprofit organization that works to improve access to care through innovative, self-sustaining health programs. FIMRC works alongside communities to improve health from the ground up — including building necessary infrastructure, such as constructing or updating buildings; ensuring communities have access to a healthcare professional; and educating on preventive health.
Learn more at fimrc.org
MicrobeTV Podcast
MicrobeTV is an independent podcast network for people who are interested in the life sciences. Our shows are about viruses, bacteria, parasites, evolution, immunology, and neuroscience.
July 21, 2022
Children and COVID-19: State level Data Report | SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses | Novavax NVX-COV2373 triggers potent neutralization of Omicron sub-lineages | CDC Recommends Novavax’s COVID-19 Vaccine for Adults | Paxlovid in patients who are immunocompromised and hospitalized with SARS-CoV-2 infection | Inhaled Fluticasone for Outpatient Treatment of Covid-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial
July 14, 2022
Neurovascular injury with complement activation and inflammation in COVID-19 | Factors Associated with Severe Outcomes Among Immunocompromised Adults Hospitalized for COVID-19 — COVID-NET, 10 States, March 2020–February 2022 | Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, & BA.5 | Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants | Parental COVID-19 Vaccine Hesitancy in Diverse Communities: A National Survey | Oral Sabizabulin for High-Risk, Hospitalized Adults with Covid-19: Interim Analysis | Rapid Diagnostic Testing for Response to the Monkeypox Outbreak — Laboratory Response Network, United States, May 17–June 30, 2022
July 8, 2022
Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation | Health Impairments in Children and Adolescents After Hospitalization for Acute COVID-19 or MIS-C | Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection | Children and COVID-19: State level Data Report | COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022 | Comparative Effectiveness of the SARS-CoV-2 Vaccines During Delta | In adults hospitalized with COVID-19, high- vs low-dose venous thromboprophylaxis reduces venous thromboembolism but increases major bleeding
June 30, 2022
Children and COVID-19: State level Data Report | Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomized, open label, superiority trial | Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic and Antibody Responses to SARS-CoV-2 in Children With COVID-19 | All-Cause Maternal Mortality in the US Before vs During the COVID-19 Pandemic
June 23, 2022
Outcomes of SARS-CoV-2 Reinfection | Children and COVID-19: State level Data Report | CDC Recommends COVID-19 Vaccines for Young Children | Evaluating clinical effectiveness of SARS-CoV-2 vaccine in solid organ transplant recipients: A propensity score matched analysis | Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters | Rebound Phenomenon after Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease-2019 in High-Risk Persons | Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment — California, December 2021–May 2022
June 16, 2022
Ivermectin for Treatment of Mild-to-Moderate COVID-19 in the Outpatient Setting: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial | Persistence of residual SARS-CoV-2 viral antigen and RNA in tissues of patients with long COVID-19 | Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19 | Rebound Phenomenon after Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease-2019 in High-Risk Persons | The anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, minimally impacts the endogenous immune response to COVID-19 vaccination
Situation Dashboards
World Health Organization (WHO)
Novel Coronavirus (COVID-19) Situation from World Health Organization (WHO)
Johns Hopkins University (JHU)
Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at JHU
COVID-19 in US and Canada
1Point3Acres Real-Time Coronavirus (COVID-19) Updates in US and Canada with Credible Sources
Genomic Epidemiology COVID-19
Genomic Epidemiology of (COVID-19) Maintained by the Nextstrain team, enabled by data from GISAID.
